Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Brefonalol

From Wikipedia, the free encyclopedia
Brefonalol
Names
IUPAC name
6-[1-Hydroxy-2-[(2-methyl-4-phenylbutan-2-yl)amino]ethyl]-3,4-dihydro-1H-quinolin-2-one
Other names
Brefanolol
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C22H28N2O2/c1-22(2,13-12-16-6-4-3-5-7-16)23-15-20(25)18-8-10-19-17(14-18)9-11-21(26)24-19/h3-8,10,14,20,23,25H,9,11-13,15H2,1-2H3,(H,24,26)
    Key: YYUZPBGIBVJYSI-UHFFFAOYSA-N
  • InChI=1/C22H28N2O2/c1-22(2,13-12-16-6-4-3-5-7-16)23-15-20(25)18-8-10-19-17(14-18)9-11-21(26)24-19/h3-8,10,14,20,23,25H,9,11-13,15H2,1-2H3,(H,24,26)
    Key: YYUZPBGIBVJYSI-UHFFFAOYAN
  • CC(C)(CCC1=CC=CC=C1)NCC(C2=CC3=C(C=C2)NC(=O)CC3)O
Properties
C22H28N2O2
Molar mass 352.478 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Brefonalol is a beta-adrenergic antagonist that reduces heart frequency and blood pressure and dilates blood vessels. It has been studied in around 1990,[1] but is not known to be marketed as of 2021.

References

[edit]
  1. Halabi, A; Endell, W; Halabi, I; Kirch, W (1990). "Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension". Journal of Cardiovascular Pharmacology. 16 (1): 81–6. doi:10.1097/00005344-199007000-00011. PMID 1696669. S2CID 41692901.